Focus Partners Wealth Boosts Position in Sanofi (NASDAQ:SNY)

Focus Partners Wealth lifted its position in shares of Sanofi (NASDAQ:SNY) by 8.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 71,808 shares of the company’s stock after purchasing an additional 5,795 shares during the quarter. Focus Partners Wealth’s holdings in Sanofi were worth $3,483,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Synergy Asset Management LLC purchased a new position in shares of Sanofi in the 4th quarter worth about $25,000. McClarren Financial Advisors Inc. increased its position in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the last quarter. Bessemer Group Inc. lifted its stake in shares of Sanofi by 59.8% in the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after purchasing an additional 242 shares during the period. Lee Danner & Bass Inc. purchased a new stake in Sanofi in the fourth quarter worth about $31,000. Finally, Sierra Ocean LLC bought a new stake in Sanofi during the 4th quarter worth approximately $44,000. Institutional investors own 14.04% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on SNY. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Hsbc Global Res upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 28th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. The Goldman Sachs Group assumed coverage on Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price target on the stock. Finally, BNP Paribas assumed coverage on Sanofi in a research report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Sanofi currently has a consensus rating of “Buy” and a consensus target price of $63.33.

Sanofi Price Performance

NASDAQ:SNY opened at $50.86 on Friday. The company has a 50 day moving average price of $53.50 and a 200-day moving average price of $51.92. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The firm has a market cap of $128.49 billion, a price-to-earnings ratio of 20.43, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The firm had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter last year, the business posted $1.78 earnings per share. The firm’s revenue was down 11.0% compared to the same quarter last year. Equities research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be paid a dividend of $2.0369 per share. This is an increase from Sanofi’s previous annual dividend of $1.48. This represents a yield of 3.1%. The ex-dividend date is Friday, May 9th. Sanofi’s dividend payout ratio is presently 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.